Pain

The panel is intended for use by physicians as an aid for safe and effective pain management.

The submission is backed by an extensive clinical and nonclinical data package comprised of 15 studies.

Submissions can include products in any stage of development and will be accepted from June 1 to September 30, 2018. The selections will be announced in November.

The NDA for the investigative long-acting subcutaneous buprenorphine injection was turned down in lieu of more data in January.

Several studies point to the links between prenatal exposure to painkillers and increased risks for ADHD and autism symptoms.

Between 3 and 9 months post-discharge, 36.9% of those aged 76+ years were prescribed an opioid, with a 5.0% incidence of long-term opioid use.

This is the first FDA-approved non-opioid treatment for the management of opioid withdrawal symptoms, providing a new option for patients to select treatment best suited to their needs.

Despite the challenges of studying the condition, researchers showed that galcanezumab significantly reduced weekly cluster headache attacks compared to placebo.

Physicians who received non-research opioid-related payments from the pharmaceutical industry in 2014 had 9.3% more opioid claims in 2015 than physicians who did not.

Researchers found that biased language affected a physician’s attitude toward a patient as well as the aggressiveness of their pain management choices.

According to survey data released by the American Psychiatric Association, almost 50% of Americans believe the crisis is impacting their peers, and 31% know someone addicted to opioids.

The BLA was originally accepted by the FDA for review in September 2017, with the product intended to be used for the treatment of immunological conditions such as rheumatoid arthritis, as well as blood cancers.

The coflex Interlaminar Stabilization disposable instrument kit is a serviceable outpatient set of injection molded instruments provided in a pre-sterilized peel pack for the posterior lumbar motion preservation solution.

Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.

Prolonged exposure to the over the counter medicine was associated with a 30% increase in the relative risk of ADHD and a 20% increase in the relative risk of ASD.

R. Presley Swann, MD discussed his preference for CPNBs when treating his patient's post-operative pain.

Trial results on the recently FDA-approved gammaCore device will be presented at the American Academy of Neurology (AAN) annual meeting.

While its safety profile was lessened, celecoxib, in comparison with naproxen and ibuprofen, remained favorable when taken with aspirin.

Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.

The likelihood that a patient would receive a new opioid prescription was higher for at-risk patients and remained true even after adjusting for demographic characteristics, comorbidities, and diagnoses associated with pain.

The therapy regimen is tolerable, safe, and effective for patients attempting to detoxify for an extended opioid agonist treatment.

Those who frequently use illicit drugs in public places were more likely to witness overdoses, and thus should be targeted for naloxone treatment training.

The Prescription Drug User Fee Act goal date, which was originally set for Q2 of 2018 after the therapy was granted Priority Review designation, has now been pushed 3 months, to Q3.

The long-acting, single-dose nerve block can now be used for popularizing procedures such as total shoulder arthroplasty or rotator cuff repair.

In a first-time issuance, all food products containing powdered kratom from Triangle Pharmanaturals, have been ordered to be recalled due to samples containing salmonella bacteria.

Researchers observed that prescribing rates were cut by about 6% in at-risk populations from states with legalization laws in place.

A study has shown that those who underestimated their prescription rates decreased opioid prescriptions by 2.2 patients more over the next 12 months after being notified of their data.

The placebo-controlled study found that the supplement reduced physiological as well as psychological symptoms of PMS.

A CDC analysis found that overall drug overdose death rates increased by 21.5%, but those involving synthetic opioids more than doubled.

Analysis including 2,848,768 deaths since 1980 has revealed increases in mortality rates due to drug abuse disorders, as well as increases in rates for self-harm and alcohol use disorders since 2000.